ATE540319T1 - Verfahren für die bestimmung von fk506 - Google Patents

Verfahren für die bestimmung von fk506

Info

Publication number
ATE540319T1
ATE540319T1 AT04811367T AT04811367T ATE540319T1 AT E540319 T1 ATE540319 T1 AT E540319T1 AT 04811367 T AT04811367 T AT 04811367T AT 04811367 T AT04811367 T AT 04811367T AT E540319 T1 ATE540319 T1 AT E540319T1
Authority
AT
Austria
Prior art keywords
levels
determining
derivatives
blood
determination
Prior art date
Application number
AT04811367T
Other languages
English (en)
Inventor
Chengrong Wang
Tie Wei
Zhu Teng
Original Assignee
Siemens Healthcare Diagnostics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siemens Healthcare Diagnostics filed Critical Siemens Healthcare Diagnostics
Application granted granted Critical
Publication of ATE540319T1 publication Critical patent/ATE540319T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9493—Immunosupressants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/825—Pretreatment for removal of interfering factors from sample

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Glass Compositions (AREA)
AT04811367T 2003-11-21 2004-11-10 Verfahren für die bestimmung von fk506 ATE540319T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/719,868 US7186518B2 (en) 2003-11-21 2003-11-21 Method and composition useful for determining FK 506
PCT/US2004/038640 WO2005052542A2 (en) 2003-11-21 2004-11-10 Method and composition useful for determining fk 506

Publications (1)

Publication Number Publication Date
ATE540319T1 true ATE540319T1 (de) 2012-01-15

Family

ID=34591451

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04811367T ATE540319T1 (de) 2003-11-21 2004-11-10 Verfahren für die bestimmung von fk506

Country Status (6)

Country Link
US (1) US7186518B2 (de)
EP (1) EP1687283B1 (de)
JP (1) JP4912887B2 (de)
AT (1) ATE540319T1 (de)
ES (1) ES2379959T3 (de)
WO (1) WO2005052542A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2424029C (en) 2000-09-29 2008-01-29 Cordis Corporation Coated medical devices
US20060222756A1 (en) * 2000-09-29 2006-10-05 Cordis Corporation Medical devices, drug coatings and methods of maintaining the drug coatings thereon
US7261735B2 (en) * 2001-05-07 2007-08-28 Cordis Corporation Local drug delivery devices and methods for maintaining the drug coatings thereon
KR20060085246A (ko) * 2003-09-18 2006-07-26 마커사이트, 인코포레이티드 경공막 전달
DK1848431T3 (en) * 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
KR20140093764A (ko) 2006-02-09 2014-07-28 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
ES2563288T3 (es) 2006-03-23 2016-03-14 Santen Pharmaceutical Co., Ltd Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
US8022188B2 (en) * 2006-04-24 2011-09-20 Abbott Laboratories Immunosuppressant binding antibodies and methods of obtaining and using same
US7642338B2 (en) * 2006-06-20 2010-01-05 Siemens Healthcare Diagnostics Inc. Tacrolimus standard and methods of using same
US7883855B2 (en) * 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
WO2008082984A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Non-denaturing lysis reagent for use with capture-in-solution immunoassay
ES2405364T3 (es) 2006-12-29 2013-05-30 Abbott Laboratories Ensayo diagnóstico para la detección de una molécula o fármaco en sangre entera
EP2118656B1 (de) * 2006-12-29 2012-08-29 Abbott Laboratories Verbessertes testverfahren für immunsuppressiva
US7914999B2 (en) * 2006-12-29 2011-03-29 Abbott Laboratories Non-denaturing lysis reagent
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
US7790401B2 (en) * 2007-08-06 2010-09-07 Siemens Healthcare Diagnostics Methods for detection of immunosuppressant drugs
US7910378B2 (en) * 2007-12-14 2011-03-22 Siemens Healthcare Diagnostics Inc. Methods for detection of hydrophobic drugs
US8084223B2 (en) * 2009-03-23 2011-12-27 Siemens Healthcare Diagnostics Inc. Detection of false results in assays
US8809003B2 (en) 2010-06-25 2014-08-19 Siemens Healthcare Diagnostics Inc. Reduction in false results in assay measurements
US8329424B2 (en) 2010-06-25 2012-12-11 Siemens Healthcare Diagnostics Reduction in false results in assay measurements
US8563298B2 (en) 2010-10-22 2013-10-22 T2 Biosystems, Inc. NMR systems and methods for the rapid detection of analytes
CA2815085C (en) 2010-10-22 2022-06-21 T2 Biosystems, Inc. Nmr systems and methods for the rapid detection of analytes
US8409807B2 (en) 2010-10-22 2013-04-02 T2 Biosystems, Inc. NMR systems and methods for the rapid detection of analytes
US8586322B2 (en) 2012-03-07 2013-11-19 Siemens Healthcare Diagnostics, Inc Sandwich assay for immunosuppressant drugs
EP2839038B1 (de) 2012-04-20 2019-01-16 T2 Biosystems, Inc. Zusammensetzungen und verfahren für den nachweis einer candida-spezies
US9658218B2 (en) * 2012-05-07 2017-05-23 Siemens Healthcare Diagnostics Inc. Determination of total analyte concentration
US9244083B2 (en) 2012-11-30 2016-01-26 Siemens Healthcare Diagnostics Inc. Compositions and methods for detecting vitamin D
US9121859B2 (en) * 2012-12-04 2015-09-01 Siemens Healthcare Diagnostics Inc. Compounds and methods for determination of FKBP-binding immunosuppressant drugs
ES2740851T3 (es) 2013-12-13 2020-02-06 Siemens Healthcare Diagnostics Inc Agente de tratamiento previo en ensayos sin aglutinación
CN106661114B (zh) 2014-06-27 2019-01-29 西门子医疗保健诊断公司 维生素d测定法中对维生素d差向异构体特异性的结合配偶体
WO2015200182A1 (en) 2014-06-27 2015-12-30 Siemens Healthcare Diagnostics Inc. Binding partners specific for vitamin d epimers
WO2016100116A1 (en) 2014-12-17 2016-06-23 Siemens Healthcare Diagnostics Inc. Sandwich assay design for small molecules
US20180306828A1 (en) 2015-10-29 2018-10-25 Siemens Healthcare Diagnostics Inc. Sandwich assay for small molecules
JP7523776B2 (ja) 2016-01-21 2024-07-29 ティー２ バイオシステムズ，インコーポレーテッド 細菌を迅速に検出するｎｍｒ法及びシステム
ES2992864T3 (en) 2018-11-02 2024-12-18 Siemens Healthcare Diagnostics Inc Binding competitors for use in macrophilin-binding pharmaceutical assays and methods of use thereof
US20220229049A1 (en) * 2019-06-28 2022-07-21 Siemens Healthcare Diagnostics Inc. Reagents for sandwich immunoassays using particle enhanced agglutination detection and methods of production and use thereof
EP4138915A4 (de) 2020-04-24 2024-04-24 Siemens Healthcare Diagnostics, Inc. Zusammensetzungen, kits und verfahren für antimikrobielle serologietests unter verwendung von anti-humanem immunglobulinantikörper

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434236A (en) 1982-10-20 1984-02-28 E. I. Du Pont De Nemours & Co. Immunoassay wherein labeled antibody is displaced from immobilized analyte-analogue
DE3886265T2 (de) 1987-06-05 1994-04-28 Fujisawa Pharmaceutical Co Anti-FR-900506-Stoffe-Antikörper und höchstempfindliches Enzym-Immunoassay-Verfahren.
DK175235B1 (da) * 1987-11-09 2004-07-19 Novartis Ag Ny anvendelse af azatricycloderivater og farmaceutiske præparater med indhold deraf
US5366971A (en) * 1987-11-09 1994-11-22 Sandoz Ltd. Use of 11,28-dioxa-4-azatricyclo[22.3.1.04,9 ]octacos-18-ene derivatives and pharmaceutical compositions containing them
US5698448A (en) 1988-12-02 1997-12-16 Soldin; Steven J. Immunosuppressive drug binding proteins and use
WO1991002736A1 (en) * 1989-08-18 1991-03-07 Fisons Plc Macrocyclic compounds
US5352671A (en) 1989-11-09 1994-10-04 Sandoz Ltd. Heteroatoms-containing tricyclic compounds
WO1991013899A1 (en) 1990-03-12 1991-09-19 Fujisawa Pharmaceutical Co., Ltd. Tricyclo compounds
WO1991017754A1 (en) * 1990-05-11 1991-11-28 Fujisawa Pharmaceutical Co., Ltd. Methods for treating and preventing inflammation of mucosa and blood vessels using fk 506 and related compounds
GB9014136D0 (en) * 1990-06-25 1990-08-15 Fujisawa Pharmaceutical Co Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same
US5227304A (en) 1991-01-16 1993-07-13 Sequoia Turner Corporation Method for counting whole blood diluent and detergent reagent system
WO1994024568A1 (en) 1993-04-20 1994-10-27 Abbott Laboratories Stable aqueous fk506 standards
US5164495A (en) * 1991-09-18 1992-11-17 Abbott Laboratories Method for preparing a dicarboxylic acid half-acid ester of FK506
ATE213272T1 (de) 1992-08-12 2002-02-15 Fujisawa Pharmaceutical Co Monoklonaler antikörper spezifisch für das fk-506-bindende protein, methode zur bestimmung des gehaltes an fk-506-bindendem protein in einer probe und reagenzsatz dafür
GB9318144D0 (en) * 1993-09-01 1993-10-20 Sandoz Ltd Organic compounds
GB9318612D0 (en) 1993-09-08 1993-10-27 Sandoz Ltd An assay
US6187547B1 (en) 1993-09-08 2001-02-13 Novartis Ag Assay kit
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
CA2175215C (en) 1993-11-19 2008-06-03 Yat Sun Or Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
MX9603838A (es) * 1994-03-10 1997-03-29 Fujisawa Pharmaceutical Co Metodo para ensayar inmunosupresores.
US5635406A (en) 1995-06-07 1997-06-03 Abbott Laboratories Stabilized standards and calibrators containing rapamycin and tacrolimus bound to anti-rapamycin and anti-tacrolimus antibodies
US5650288A (en) 1995-07-14 1997-07-22 Macfarlane; Gordon D. Immunophilin-bound immunosuppressant assay
US5936401A (en) * 1996-09-19 1999-08-10 The United States Of America As Represented By The Secretary Of The Air Force Device and process for measuring electrical properties at a plurality of locations on thin film superconductors
GB9815696D0 (en) 1998-07-20 1998-09-16 Pfizer Ltd Heterocyclics

Also Published As

Publication number Publication date
WO2005052542A2 (en) 2005-06-09
JP4912887B2 (ja) 2012-04-11
JP2007512340A (ja) 2007-05-17
WO2005052542A3 (en) 2005-12-01
EP1687283B1 (de) 2012-01-04
EP1687283A2 (de) 2006-08-09
EP1687283A4 (de) 2008-09-24
ES2379959T3 (es) 2012-05-07
US7186518B2 (en) 2007-03-06
US20050112778A1 (en) 2005-05-26

Similar Documents

Publication Publication Date Title
ATE540319T1 (de) Verfahren für die bestimmung von fk506
ATE230487T1 (de) Verfahren zur frühen diagnose von carcinomen
ATE424560T1 (de) Marker für neuromyelitis optica
WO2004063704A3 (en) Vitamin d assay
ATE425266T1 (de) Aptamer-nanopartikelkonjugate und verwendungsverfahren zur detektion von zielanalyten
ATE480643T1 (de) Homogener nachweis von analyten
DE60133982D1 (de) Biosensor und verfahren zum analysieren von blutkomponenten
ATE431854T1 (de) Auf bio-barcodes beruhender nachweis von zielanalyten
WO2006036744A3 (en) Methods for a global assay of coagulation and fibrinolysis
DE50010710D1 (de) Verfahren zur bestimmung von substanzen mittels der evaneszenzfeldmethode
WO2006001931A3 (en) Prouroguanylin as therapeutic and diagnostic agents
EP1643894A4 (de) Verfahren, kits und antikörper zum nachweis von parathyroid
DE60325382D1 (de) Verfahren zur diagnose von gebärmutterhalskrebs
WO2003087761A3 (en) Molecular profiling of disease and therapeutic response using phospho-specific antibodies
ATE347105T1 (de) Verfahren, assay und kit zur quantifizierung von hiv-proteasehemmer
EP1566448A3 (de) Differenzialdiagnostik mit Hepcidin
EP1572225A4 (de) Thrombospondinfragmente und deren verwendung bei klinischen krebs-tests und der erzeugung von antikörpern und sonstigen bindungsmitteln
WO2004109286A3 (en) Methods for detecting and treating cancer using podocalyxin and/or endoglycan
ATE408832T1 (de) Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper
WO2004113574A3 (en) Methods for disease screening
ATE383418T1 (de) Verfahren und zusammensetzungen zur bestimmung glycierter proteine
DE50101520D1 (de) Kompetitives assay-verfahren
ATE365321T1 (de) Verfahren zur erkennung von entzündungen und entzündungsbedingungen
WO2006096697A3 (en) Methods for determining the bivalency of protein and antibody therapeutics
DE602004029589D1 (de) Testverfahren zur bestimmung von analyten mittels analytanalogen